Felzartamab Shows Promise for Late Antibody-Mediated Kidney Transplant Rejection

Facebook
Pinterest
Twitter
LinkedIn

Human Immunology Biosciences (HI-Bio), a leading clinical-stage biotech company focused on developing targeted therapies for severe immune-mediated diseases, has announced promising results from its Phase 2 investigator-sponsored clinical trial of felzartamab. The study aimed to evaluate the efficacy of felzartamab in treating late antibody-mediated rejection (ABMR) in kidney transplant recipients.

The positive findings from this trial suggest that felzartamab could potentially address a significant unmet medical need for patients experiencing late ABMR, a severe complication that can lead to graft loss and reduced patient survival. HI-Bio’s commitment to developing innovative therapies for immune-mediated diseases is further strengthened by these encouraging results.

The company plans to continue its research and development efforts to bring felzartamab closer to regulatory approval and commercial availability, offering hope to kidney transplant recipients facing the challenges of late ABMR.